Multicenter study of cisplatin-based chemotherapy with short hydration for lung cancer patients

Multicenter study of cisplatin-based chemotherapy with short hydration for lung cancer patients - Multicenter study of cisplatin-based chemotherapy with short hydration for lung cancer patients

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010201

Enrollment

Registered

2013-04-01

Start date

2013-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

hydration(intravenous, oral), antiemetics

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Histologically or cytologically diagnosed lung cancer 2. Cisplatin (60mg/m2 or over)-based chemotherapy 3. Without treatment history of cisplatin 4. 20-74 year old 5. ECOG Performance Status 0 - 1 6. Appropriate organ function 7. Normal kidney function (1) Cr value under normal limit (2) Creatinine clearance over 60ml/min

Exclusion criteria

Exclusion criteria: 1. Comorbidity (congestive heart failure, angina, myocardial infarction) 2. Pleural effusion, pericardial effusion, ascites, brain metastases, bone metastases which needs intervention 3. Active infection 4. Steroid treatment

Design outcomes

Primary

Measure	Time frame
Proportion of patients without grade 2 or worse elevation of creatinine after cisplatin-based chemotherapy	—

Countries

Japan

Contacts

Public ContactHidehito Horinouchi

National Cancer Center Hospital Thoracic oncology

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026